# Bachem

Type: Company (BCHMF)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bachem
Canonical HTML page: https://getbiobrief.com/entity/bachem

## Timeline

- **2026-03-24**: Analyst Sentiment Review — Major firms maintain ratings, citing steady execution of the strategic pivot.
- **2026-03-12**: 2026 Guidance Issued — Management outlines $72M-$76M revenue target driven by ECO Synthesis.
- **2026-03-11**: Q4 2025 Earnings Release — Codexis reports significant beats on both top and bottom lines.

## Recent coverage (2 stories)

### Codexis Sustains Analyst Confidence Following Q4 Beat and 2026 Revenue Guidance
2026-03-24 23:00:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Full story: https://getbiobrief.com/story/codexis-cdxs-earnings-analyst-sentiment-2026

### Bachem Earnings Preview: Peptide Capacity and GLP-1 Demand in Focus
2026-03-11 07:27:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bachem (BCHMF) is set to release its quarterly earnings this Thursday, with investors closely monitoring the Swiss CDMO's ability to scale production for the booming GLP-1 market. As a critical supplier of peptides and oligonucleotides, Bachem's financial performance and capacity expansion updates will serve as a bellwether for the broader weight-loss drug supply chain.
Full story: https://getbiobrief.com/story/bachem-earnings-preview-peptide-capacity-glp1-demand

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.